image
Healthcare - Medical - Instruments & Supplies - NYSE - CH
$ 85.13
-0.047 %
$ 42 B
Market Cap
39.41
P/E
1. INTRINSIC VALUE

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery.[ Read More ]

The intrinsic value of one ALC stock under the base case scenario is HIDDEN Compared to the current market price of 85.1 USD, Alcon Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALC

image
FINANCIALS
10.1 B REVENUE
15.77%
1.04 B OPERATING INCOME
54.61%
1.04 B NET INCOME
210.33%
1.48 B OPERATING CASH FLOW
21.73%
-1.09 B INVESTING CASH FLOW
41.34%
-211 M FINANCING CASH FLOW
-2537.50%
2.51 B REVENUE
2.12%
318 M OPERATING INCOME
-13.59%
223 M NET INCOME
-10.08%
545 M OPERATING CASH FLOW
59.72%
-133 M INVESTING CASH FLOW
38.99%
-171 M FINANCING CASH FLOW
-159.09%
Balance Sheet Decomposition Alcon Inc.
image
Current Assets 5.65 B
Cash & Short-Term Investments 1.1 B
Receivables 2.11 B
Other Current Assets 2.43 B
Non-Current Assets 24 B
Long-Term Investments 148 M
PP&E 4.72 B
Other Non-Current Assets 19.1 B
Current Liabilities 2.48 B
Accounts Payable 811 M
Short-Term Debt 216 M
Other Current Liabilities 1.45 B
Non-Current Liabilities 6.51 B
Long-Term Debt 4.93 B
Other Non-Current Liabilities 1.58 B
EFFICIENCY
Earnings Waterfall Alcon Inc.
image
Revenue 10.1 B
Cost Of Revenue 4.48 B
Gross Profit 5.61 B
Operating Expenses 4.21 B
Operating Income 1.04 B
Other Expenses -613 K
Net Income 1.04 B
RATIOS
55.57% GROSS MARGIN
55.57%
10.30% OPERATING MARGIN
10.30%
9.65% NET MARGIN
9.65%
4.72% ROE
4.72%
3.29% ROA
3.29%
4.80% ROIC
4.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alcon Inc.
image
Net Income 1.04 B
Depreciation & Amortization 1.3 B
Capital Expenditures -908 M
Stock-Based Compensation 144 M
Change in Working Capital -431 M
Others -402 M
Free Cash Flow 573 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alcon Inc.
image
Wall Street analysts predict an average 1-year price target for ALC of $100 , with forecasts ranging from a low of $76 to a high of $110 .
ALC Lowest Price Target Wall Street Target
76 USD -10.72%
ALC Average Price Target Wall Street Target
100 USD 17.47%
ALC Highest Price Target Wall Street Target
110 USD 29.21%
4. DIVIDEND ANALYSIS
0.30% DIVIDEND YIELD
0.264 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Alcon Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Alcon: Q3, Slight Guidance Cut Is Not Something Structural I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $118 per share, despite a minor guidance cut. Alcon's new product launches, including PRECISION7 and Systane Pro, are expected to drive significant growth in the vision segment. Alcon's surgical business, with a strong position in cataract surgery, is projected to grow 7% annually, driven by advanced technology and international expansion. seekingalpha.com - 3 days ago
Alcon (ALC) Q3 2024 Earnings Call Transcript Alcon Inc. (NYSE:ALC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Dan Cravens - Vice President, Investor Relations Conference Call Participants Graham Doyle - UBS Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Co. Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Ryan Zimmerman - BTIG Jeff Johnson - Baird Anthony Petrone - Mizuho Tom Stephan - Stifel Brett Fishbin - Keybanc Capital Markets David Adlington - JP Morgan Giang Nguyen - Citi Issie Kirby - Redburn Atlantic Sajid Aznar - HSBC Falco Freidrichs - Deutsche Bank Operator Greetings and welcome to the Alcon third quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 days ago
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team. zacks.com - 3 days ago
Alcon cuts 2024 forecasts, as slow US hits surgical unit Eye-care group Alcon cut its 2024 forecasts and missed market expectations for third-quarter sales on Tuesday evening, as a soft U.S. market hit its surgical business. reuters.com - 4 days ago
Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 4 days ago
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation GENEVA--(BUSINESS WIRE)--Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation. businesswire.com - 4 days ago
What Analyst Projections for Key Metrics Reveal About Alcon (ALC) Q3 Earnings Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alcon (ALC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024. zacks.com - 1 week ago
Algoma Central Corporation to Issue Third Quarter Financial Results on November 4, 2024 ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (TSX: ALC) today announced it will report its financial results for the three and nine months ended September 30, 2024 before market open on November 4, 2024. The Company's third quarter earnings release and full financial results will be available on the Company's website and on SEDAR. Algoma Central Corporation is a global provider of marine transportation that owns and operates dry and liquid bulk carriers, serving markets. businesswire.com - 3 weeks ago
Reasons to Retain Alcon Stock in Your Portfolio for Now Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC. zacks.com - 1 month ago
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care. zacks.com - 1 month ago
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It? Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale. investors.com - 2 months ago
Alcon Analysts Increase Their Forecasts After Q2 Results Alcon Inc. ALC reported mixed second-quarter results, after the closing bell on Tuesday. benzinga.com - 2 months ago
8. Profile Summary

Alcon Inc. ALC

image
COUNTRY CH
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 42 B
Dividend Yield 0.30%
Description Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Contact Chemin de Blandonnet 8, Geneva, 1214 https://www.alcon.com
IPO Date April 9, 2019
Employees 25000
Officers Mr. F. Michael Ball Executive Chairman Margaret Buckley Chief Accounting Officer Mr. Leon Sergio Duplan Fraustro President of North America Ms. Kimberly Martin Senior Vice President, Chief HR Officer & Corporate Communications Mr. Ian Bell Senior Vice President & Chief Operating Officer Mr. Timothy C. Stonesifer Chief Financial Officer Mr. Arthur B. Cummings M.D. Executive Director Dr. Franck Leveiller Senior Vice President, Head of Global R&D and Chief Scientific Officer Mr. David J. Endicott Chief Executive Officer & Director Mr. Laurent Attias Head of Corporate Development, Strategy, BD&L and M&A